Metastasis to buccinator lymph nodes from upper gingival cancer is rare, and indicates a poor prognosis. We suggest that the ...

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved outcomes post-surgery and radiation.

A 63-year-old woman with a 20-year history of hidradenitis suppurativa, classified as Hurley Stage III (a disease-specific staging system); a 12 pack-year smoking history; pyoderma gangrenosum; and ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

MSK radiation oncologist Dr. Nancy Lee helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers. A phase 3 clinical trial ...

Expanding the industry’s most comprehensive portfolio of AI applicationsPHILADELPHIA and PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Proscia®, a pathology AI company, will add AI biomarker detection for ...